Skip to main content

Table 1 Number and age of patients included in the analysis

From: Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa

Site and Country Reference Age (year) ASAQ AL AQ AQ + SP AS + SP AS CQ + SP DP Total
Median Mininum Maximum
Burkina Faso [9] 2.0 0.5 5 750         750
Cameroon [7] 6.2 1.0 65 110 56        166
Gabon [8]* 5.5 1.3 11 108   110       218
Madagascar [9] 7.4 1.4 53 119 60        179
Mali, Boulouga [7] 4.7 0.9 24 135 68        203
Mali, Bancoumana [10] 3.0 0.6 56 252     249 252    753
Rwanda, Kicukiro [11]* 3.3 1.0 5 74    74     75 223
Rwanda, Mashesha [11]* 3.0 1.1 5 89    93     87 269
Rwanda, Rukara [11]* 2.1 1.0 5 89    91     90 270
Senegal, Keur-Socé [7] 9.0 1.0 15 264 128        392
Senegal, Mlomp [11]* 5.0 0.9 64 160   160       320
Uganda, Apac [13]* 1.8 0.5 47 174    183    185   542
Uganda, Jinja [13]* 3.6 0.5 65 189    186    168   543
Uganda, Tororo [13, 14]* 1.6 0.5 56 398 204   181    166   949
Zanzibar, Kivungue [12] 2.5 0.5 7 148 149        297
Zanzibar, Micheweni [12] 2.1 0.5 5 54 51        105
Total   3.0 0.5 65 3113 716 270 808 249 252 519 252 6179
  1. Legend: * studies including grading of intensity AQ, amodiaquine; AL, artemether-lumefantrine; AS, artesunate; DP, dihydroartemisinin-piperaquine; CQ, chloroquine; SP, sulphadoxine-pyrimethamine.